Overview

Evaluation of the efficacy and safety of adding rituximab after failure of target immunotherapy in the Posterior treatment of advanced hepatocellular carcinoma

Eligibility

Inclusion Criteria:

• 1)written informed consent signed prior to enrolment.
• 2\) Age 17-79 years old (including boundary), male or female;
• 3\) Subjects with histologically or cytologically confirmed advanced hepatocellular carcinoma (HCC), or clinical diagnosis that meets the American Association of Liver Diseases (AASLD) diagnostic criteria for hepatocellular carcinoma
• 4\) Previous progression or intolerance after failure to target, immunization, or conventional therapy (including TKI, ICI, chemotherapy, VEGF monoclonal antibody, or ICI combined with TKI/VEGF monoclonal antibody/chemotherapy)
• 5\) 2 weeks after the end of previous systemic therapy ≥ the first dose of this study, and the treatment-related AEs recovered to NCI-CTCAE ≤ Grade 1 (except for alopecia)
• 6\) Child-Pugh liver function rating within 7 days prior to the first dose of the study drug: A grade and good B grade (≤ 7 points)
• 7\) Phase B or C as assessed by BCLC or Phase III as assessed by CNLC
• 8\) At least one measurable target lesion as assessed by the investigator according to the requirements of mRECIST v1.1 within 4 weeks prior to the first dose
• 9\) Have adequate organ function (without receiving blood transfusion, erythropoietin, granulocyte colony-stimulating factor, albumin, or other medical support within 14 days prior to initiation of study drug therapy)
• 10\) If the patient has HBsAg(+) or HBcAb(+), HBV-DNA must be \< 2500 copies/mL or \< 500 IU/mL or \< upper limit of normal (ULN) to be enrolled, and those with elevated HBV-DNA must agree to receive nucleoside anti-hepatitis B virus therapy. Subjects who are negative for HCV antibody (-) or HCV-RNA are allowed to enroll, if HCV-RNA is positive, they need to agree to receive local standard standard antiviral therapy, and subjects must have ALT, AST, ≤ 3×ULN to enroll, and subjects with hepatitis B and C co-infection need to be excluded (HBV-DNA and HCV-RNA are positive)
• 11\) Patients with cured hepatitis C are acceptable, and the lower limit of detection of HCV RNA \< test center before starting study drug treatment
• 12\) ECOG PS score: 0-1
• 13\) Expected survival ≥ 12 weeks
• 14\) Male or female of childbearing potential who are willing to use contraception in the trial, and females of childbearing potential must have a pregnancy test within 7 days prior to the first dose with a negative result
• 15)CD20 positive and CD20 scattered (non aggregated) distribution in tumors

Exclusion Criteria:

• 1\) Known hepatocholangiocarcinoma, mixed cell carcinoma, or fibrolamellar cell carcinoma
• 2\) History of hepatic encephalopathy within 6 months prior to the first dose of this study
• 3\) Portal hypertension with endoscopic red signs, or those who are considered by the investigator to have a high risk of bleeding or who have had esophageal or gastric variceal bleeding within 6 months before the first dose
• 4\) Symptomatic brain or meningeal metastases (unless the patient has been \>treated for 3 months, there is no evidence of progression in imaging results within 4 weeks before the first dose, and tumor-related clinical symptoms are stable)
• 5\) The patient has human immunodeficiency virus (HIV) or active tuberculosis, or other uncontrolled active infection
• 6\) Those who have undergone major surgery within 4 weeks before enrollment, and those who have had bone marrow biopsy, open biopsy, and intracranial biopsy within 7 days before screening
• 7\) Those who have other malignant tumors in the past 5 years and have not been effectively controlled, except for carcinoma in situ of the cervix, squamous cell carcinoma of the skin or localized basal cell skin cancer
• 8\) Known history of severe allergy to any monoclonal antibody or study drug excipient
• 9\) Pregnant or lactating women
• 10\) Other reasons judged by the investigator to be unsuitable for participating in this study